Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC S versus BRIMONIDINE TARTRATE TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC S versus BRIMONIDINE TARTRATE TIMOLOL MALEATE.
BETOPTIC S vs BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
Instill 1 drop in the affected eye(s) twice daily.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance.
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces.
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Category C
Category A/B
Beta-Blocker
Beta-Blocker